Immunogenicity of 10 and 20 μg hepatitis B vaccine in a two-dose schedule

Najib Ul-Haq; Syed S. Hasnain; Muhammad Umar; Zaigham Abbas; Carmen Valenzuela-Silva; Pedro Lopez-Saura

doi:10.1016/S0264-410X(03)00232-9

Immunogenicity of 10 and 20 μg hepatitis B vaccine in a two-dose schedule

Najib Ul-Haq
, Syed S. Hasnain
, Muhammad Umar
, Zaigham Abbas
, Carmen Valenzuela-Silva
, Pedro Lopez-Saura

Research output: Contribution to journal › Article › peer-review

35 Citations (Scopus)

Abstract

Healthy subjects (15-50 years old) were randomised to receive, intramuscularly, 10 or 20μg of a yeast-derived recombinant hepatitis B vaccine (Heberbiovac HB) on a two-dose (0-1) schedule. Anti-hepatitis B surface antigen antibodies (HBsAb) were determined at 2, 3 and 6 months. Twenty micrograms immunisation yielded 96.3% seroprotection (HBsAb >10IU/l) at t=3, which persisted to 97.2% at t=6. The 10μg group resulted in 87.4% seroprotection at t=3 and 81% at t=6, but reached >95% among subjects <21 years old, both at t=3 and 6. It is concluded that the vaccine used is highly immunogenic and the two-dose 20μg immunisation can be used in all age groups and 10μg in subjects up to 20 years. These schedules can result in significantly better compliance and cost-effectiveness of the vaccination programs.

Original language	English (UK)
Pages (from-to)	3179-3185
Number of pages	7
Journal	Vaccine
Volume	21
Issue number	23
DOIs	https://doi.org/10.1016/S0264-410X(03)00232-9
Publication status	Published - 4 Jul 2003
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Recombinant hepatitis B vaccine
Two-doses

Access to Document

10.1016/S0264-410X(03)00232-9

Cite this

@article{e3b9adb399164d1584cbed6e32c37ffb,

title = "Immunogenicity of 10 and 20 μg hepatitis B vaccine in a two-dose schedule",

abstract = "Healthy subjects (15-50 years old) were randomised to receive, intramuscularly, 10 or 20μg of a yeast-derived recombinant hepatitis B vaccine (Heberbiovac HB) on a two-dose (0-1) schedule. Anti-hepatitis B surface antigen antibodies (HBsAb) were determined at 2, 3 and 6 months. Twenty micrograms immunisation yielded 96.3\% seroprotection (HBsAb >10IU/l) at t=3, which persisted to 97.2\% at t=6. The 10μg group resulted in 87.4\% seroprotection at t=3 and 81\% at t=6, but reached >95\% among subjects <21 years old, both at t=3 and 6. It is concluded that the vaccine used is highly immunogenic and the two-dose 20μg immunisation can be used in all age groups and 10μg in subjects up to 20 years. These schedules can result in significantly better compliance and cost-effectiveness of the vaccination programs.",

keywords = "Recombinant hepatitis B vaccine, Two-doses",

author = "Najib Ul-Haq and Hasnain, \{Syed S.\} and Muhammad Umar and Zaigham Abbas and Carmen Valenzuela-Silva and Pedro Lopez-Saura",

year = "2003",

month = jul,

day = "4",

doi = "10.1016/S0264-410X(03)00232-9",

language = "English (UK)",

volume = "21",

pages = "3179--3185",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "23",

}

TY - JOUR

T1 - Immunogenicity of 10 and 20 μg hepatitis B vaccine in a two-dose schedule

AU - Ul-Haq, Najib

AU - Hasnain, Syed S.

AU - Umar, Muhammad

AU - Abbas, Zaigham

AU - Valenzuela-Silva, Carmen

AU - Lopez-Saura, Pedro

PY - 2003/7/4

Y1 - 2003/7/4

N2 - Healthy subjects (15-50 years old) were randomised to receive, intramuscularly, 10 or 20μg of a yeast-derived recombinant hepatitis B vaccine (Heberbiovac HB) on a two-dose (0-1) schedule. Anti-hepatitis B surface antigen antibodies (HBsAb) were determined at 2, 3 and 6 months. Twenty micrograms immunisation yielded 96.3% seroprotection (HBsAb >10IU/l) at t=3, which persisted to 97.2% at t=6. The 10μg group resulted in 87.4% seroprotection at t=3 and 81% at t=6, but reached >95% among subjects <21 years old, both at t=3 and 6. It is concluded that the vaccine used is highly immunogenic and the two-dose 20μg immunisation can be used in all age groups and 10μg in subjects up to 20 years. These schedules can result in significantly better compliance and cost-effectiveness of the vaccination programs.

AB - Healthy subjects (15-50 years old) were randomised to receive, intramuscularly, 10 or 20μg of a yeast-derived recombinant hepatitis B vaccine (Heberbiovac HB) on a two-dose (0-1) schedule. Anti-hepatitis B surface antigen antibodies (HBsAb) were determined at 2, 3 and 6 months. Twenty micrograms immunisation yielded 96.3% seroprotection (HBsAb >10IU/l) at t=3, which persisted to 97.2% at t=6. The 10μg group resulted in 87.4% seroprotection at t=3 and 81% at t=6, but reached >95% among subjects <21 years old, both at t=3 and 6. It is concluded that the vaccine used is highly immunogenic and the two-dose 20μg immunisation can be used in all age groups and 10μg in subjects up to 20 years. These schedules can result in significantly better compliance and cost-effectiveness of the vaccination programs.

KW - Recombinant hepatitis B vaccine

KW - Two-doses

UR - https://www.scopus.com/pages/publications/0037866956

U2 - 10.1016/S0264-410X(03)00232-9

DO - 10.1016/S0264-410X(03)00232-9

M3 - Article

C2 - 12804846

AN - SCOPUS:0037866956

SN - 0264-410X

VL - 21

SP - 3179

EP - 3185

JO - Vaccine

JF - Vaccine

IS - 23

ER -

Immunogenicity of 10 and 20 μg hepatitis B vaccine in a two-dose schedule

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this